Format

Send to

Choose Destination
Br J Cancer. 2007 Dec 3;97(11):1465-8. Epub 2007 Oct 23.

Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy.

Author information

1
Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. schontha@usc.edu

Abstract

Celecoxib (Celebrex) was developed as a selective cyclooxygenase-2 (COX-2) inhibitor for the treatment of chronic pain. However, it now appears that this compound harbours additional pharmacologic activities that are entirely independent of its COX-2-inhibitory activity. This review presents the recently emerged direct non-COX-2 targets of celecoxib and their proposed role in mediating this drug's antitumour effects.

PMID:
17955049
PMCID:
PMC2360267
DOI:
10.1038/sj.bjc.6604049
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center